Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the acute and late toxicities from radiation
therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks
for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2
years).